HARBOR missed on 8 September 2026. The NO-GO was sealed 1,235 days earlier.
BVCT sealed a FAILURE call on AOC 1001 (No. 999) on , at Phase 1/2, and again on del-desiran at Phase 3 (No. 2157) on . On , Novartis announced that HARBOR missed its primary endpoint, vHOT. The dashboard classifies that readout as True Negative (TN) (No. 999) and True Negative (TN) (No. 2157).
BVCT simulates the mechanism in virtual patients, not the trial's data — so superiority to standard of care is known before the readout.
On , Novartis announced that the Phase III HARBOR study of del-desiran (AOC 1001) in myotonic dystrophy type 1 did not demonstrate a statistically significant improvement versus placebo on its primary endpoint, video hand opening time (vHOT).
BVCT sealed a FAILURE call on this asset on — 1,235 days earlier, when AOC 1001 was still a Phase 1/2 programme at Avidity Biosciences, and 1,042 days before the acquisition of the company was completed. We wrote to Novartis’ leadership on with our predictions for all three of Avidity’s lead assets, three months before the acquisition was completed.
BVCT further sealed the call a second time at Phase 3 on , naming vHOT — the primary endpoint — among those that would not separate from placebo. That prediction was sent to Novartis’ leadership on — 42 days before the readout.
BVCT’s patient-data-free causal simulation of clinical benefit is independent of development phase.
NO-GO · Avidity Biosciences (RNA) · AOC 1001 (anti-TfR1 antibody–siRNA conjugate) · MARINA · Phase 1/2 · 38 patients · 6 months/patient · Myotonic Dystrophy Type 1. Outcome: the asset advanced to Phase 3 as del-desiran and was acquired by Novartis. On HARBOR missed its primary endpoint. CORRECT — called 1,235 days in advance, at Phase 1/2. The dashboard classifies the readout as True Negative (TN). BVCT PandaDoc Ref: 7XKA3-CGA8C-ZCNBY-9A3AG. See No. 999 on the dashboard.
FAILURE (statistically insignificant clinical benefit in vHOT and 10MWT compared with placebo)
Commercial Prediction
FAILURE (commercially insufficient clinical benefit in vHOT and 10MWT slightly inferior to DYNE101 with RR > 1.2 and moderately inferior to PGN-EDODM1 with RR > 1.4)
NO-GO · Novartis AG · Del-desiran (AOC 1001) · HARBOR · Phase 3 · 159 patients · 54 weeks/patient · Myotonic Dystrophy Type 1. Sent to Novartis’ leadership on , 42 days before the readout. Outcome: HARBOR did not demonstrate a statistically significant improvement versus placebo on the primary endpoint, vHOT. CONFIRMED ON THE PRIMARY ENDPOINT — called 44 days in advance · 10MWT not yet adjudicable. The dashboard classifies the readout as True Negative (TN). Source: Novartis announcement, . BVCT PandaDoc Ref: SVNRK-XSFDD-PQ87M-LSBOB. See No. 2157 on the dashboard.
The Timeline.
THE CALLS, THE DEAL, THE READOUT — IN SEQUENCE
BVCT sealed No. 999 — FAILURE on AOC 1001, then a Phase 1/2 asset at Avidity. 1,235 days before readout.
MARINA Phase 1/2 data filed with the SEC on Form 8-K: the vHOT improvement at 4 mg/kg was numerical; significance versus placebo came only from a post-hoc analysis (Form 8-K exhibit). In our view, the signal was read as encouraging.
Novartis announced an agreement to acquire Avidity Biosciences.
BVCT shared its prediction record and performance data with Novartis’ leadership. 287 days before readout.
Acquisition completes at USD 72.00 per share. About USD 12bn in total equity value.
BVCT seals No. 2157 — FAILURE in vHOT and 10MWT. 44 days before readout.
Sent to the Novartis leaders in the Top 10 2H 2026 prediction letter. 42 days before readout.
HARBOR misses its primary endpoint. vHOT did not separate from placebo.
Why Phase Does Not Matter.
A first-in-class asset is the hardest thing in the industry to derisk, for a simple reason: there is no precedent data to extrapolate from.
BVCT simulates the causal mechanism of the drug against the disease biology in virtual patients, and BVCT outputs a quantified clinical effect size against a named comparator, the entirety of which does not depend on how much clinical data exists yet.
AOC 1001 is a clean demonstration: two calls, one verdict — the first sealed before MARINA’s topline, before HARBOR enrolled a patient, and 1,235 days before the readout confirmed it.
Immune to the Early Signal That Pointed the Wrong Way.
Administer a drug, wait, and sponsors learn whether an endpoint moved — but rarely why.
For decades, this lack of mechanistic insight has been the ultimate blind spot in clinical development.
It is also precisely why BeatSoC Virtual Clinical Trials (BVCT) can help pharma identify false-positive early signals before capital is committed — and before patients are enrolled.
BVCT is a clinical de-risking capability built to identify false-positive early clinical signals.
What This Changes for a Portfolio Decision.
BVCT — BeatSoC Virtual Clinical Trial — is a prospective, patient-data-independent, pre-readout clinical de-risking platform. It uses proprietary virtual patients to simulate causal, deterministic clinical effect sizes without patient-level data from the trial being predicted, or from any prior trial. Each simulation functions as a head-to-head phase-3-scale quantification of a novel therapy against a named comparator standard of care — regardless of the programme’s actual stage of development.
Because BVCT’s input is the mechanism and not the data, BVCT’s output is also immune to a false-positive early efficacy signal that later fails to replicate. A NO-GO call lets a sponsor decline programmes unlikely to deliver superior benefit and concentrate resources where the benefit is real — which is why, in our view, BVCT can prevent billion-dollar R&D and BD&L budgets from becoming sunk costs before they are committed.
BVCT’s prospective record now stands at 674 of 705 sealed ex-ante clinical predictions confirmed by readout — 95.6% accuracy, 89.7% PPV (GO calls), 99.1% NPV (NO-GO calls), F1 of 93.8% — against a 7.9% industry baseline (BIO / QLS / Informa 2011–2020 Likelihood of Approval from Phase 1). AOC 1001 is one sealed pair within it.
A NO-GO call lets a sponsor decline programmes unlikely to deliver superior benefit — and concentrate resources on the programmes that earn a GO.
Seven days per asset. Before the first patient enrollment.
Name any asset you are weighing — at any phase, including preclinical and first-in-class. Receive a simulated Phase-3 effect size, a GO / NO-GO call against a named comparator, and the mechanistic root cause behind it — within one week. No patient data required. Sealed and timestamped, exactly as No. 999 and No. 2157 were.
Clinical Foresight Before Decisions. Earlier is Kinder for Patients.